Patient Engagement Collaboratives Are Talking—but Are They Driving Real Change?
The upcoming joint meeting between the CTTI/FDA Patient Engagement Collaborative (PEC) and the EMA Patients and Consumers Working Party (PCWP) is being heralded as a milestone in cross-continental patient involvement.…
When Activist Investors Dictate Healthcare Leadership: The Case of STAAR’s Board Shakeup
The recent overhaul at STAAR, driven by an activist investor that resulted in the ousting of both the CEO and board chair, is more than just another headline in healthcare…
The ‘Great Healthcare Plan’: A Missed Opportunity Cloaked in Vagueness
The so-called ‘Great Healthcare Plan’ is emblematic of a broader issue in healthcare policy communication: ambiguity that hinders strategic marketing and stakeholder engagement. For healthcare marketers, clarity is non-negotiable. This…
Strategic Leadership: The Overhyped Panacea or the Real Catalyst for Healthcare’s Future?
The current industry obsession with “strategic leadership” in healthcare risks becoming a buzzword devoid of actionable insight. While the article rightly positions leadership as central to progress, it stops short…
Kidney Care Innovation: Medtech’s Next Frontier or Overhyped Trend?
The recent declaration by a medtech venture capital firm that kidney care is entering a new era of innovation is both timely and expected, but it warrants a critical lens.…
JPM26 Deal Activity Disappoints, But Signals Deeper Industry Shifts in Pharma and Medtech
The tepid dealmaking observed at JPM26 should not be mistaken for stagnation in the healthcare sector. Instead, it highlights a deeper recalibration as pharmaceutical companies brace for the impending patent…
The HMA/EMA AI Workshop: A Missed Opportunity for Proactive Industry Leadership
The upcoming HMA/EMA multi-stakeholder workshop on artificial intelligence, scheduled for November 2025, ostensibly promises a critical forum for dialogue among regulators, industry players, and other stakeholders. However, as a healthcare…
EMA’s Upcoming Webinar on New Variations Guidelines: A Critical Opportunity or Another Regulatory Tick-Box?
The European Medicines Agency’s announcement of a webinar on the new variations guidelines for marketing authorisation holders (human) scheduled for January 13, 2026, signals yet another regulatory update that healthcare…
EMA-EUCOPE Meeting: A Missed Opportunity for Meaningful Industry-Regulator Dialogue
The announcement of the fourth bilateral meeting between the European Medicines Agency (EMA) and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) might seem routine, but it underscores a persistent challenge…
Fresenius CEO’s Call for a Healthcare ‘Fundamental Rethink’ Masks Deeper Industry Failures
Fresenius CEO’s remarks at Davos26 about the need for a “fundamental rethink” in healthcare delivery are less a visionary call to action and more a glaring indictment of how stagnant…